Form 4: Moderna CLO's Planned Stock Transactions Under 10b5-1

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported planned acquisitions of common stock from RSU conversions and subsequent tax-related dispositions under a 10b5-1 plan.

Summary

• Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., reported planned transactions under a Rule 10b5-1 plan.
• On November 26, 2025, Klinger acquired 773 shares of Moderna common stock through the conversion of restricted stock units (RSUs).
• Concurrently on November 26, 2025, 374 shares were disposed of at $24.75 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Klinger directly beneficially owned 28,569 shares of common stock.
• On November 28, 2025, Klinger acquired an additional 329 shares of Moderna common stock from RSU conversions.
• Also on November 28, 2025, 160 shares were disposed of at $25.01 per share to satisfy tax withholding obligations.
• After all reported transactions, Klinger directly beneficially owned 28,738 shares of common stock.
• RSUs convert to common stock on a one-for-one basis.
• One RSU award (773 shares) had 25% vest on February 27, 2025, with the remainder vesting in twelve equal quarterly installments.
• Another RSU award (329 shares) had 25% vest on February 28, 2024, with the remainder vesting in twelve equal quarterly installments.

Sentiment

Score: 6

Explanation: The filing reports routine, pre-scheduled insider transactions (RSU vesting and tax-related sales) under a 10b5-1 plan. While not indicative of new operational news, the continued vesting and retention of a significant number of shares by a key executive is generally a neutral to slightly positive signal regarding management's long-term alignment with shareholder interests.

Positives

• The transactions are part of a pre-arranged 10b5-1 plan, indicating structured and compliant insider trading.
• The acquisition of shares through RSU conversions increases the insider's direct ownership, aligning management interests with shareholders.

Negatives

• A portion of the acquired shares was immediately sold to cover tax obligations, which is a common practice but reduces the net increase in direct ownership.

Future Outlook

The filing indicates future vesting events for restricted stock units, with remaining installments scheduled quarterly after February 27, 2025, for one award, and after February 28, 2024, for another. These are pre-scheduled events.

Industry Context

This Form 4 filing reports routine insider transactions related to equity compensation. Such filings are common across all publicly traded companies, particularly for executives whose compensation packages often include restricted stock units or options. It does not provide specific insights into Moderna's operational performance or broader industry trends, but rather reflects standard executive compensation practices.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a component of executive compensation is a standard practice across the biotechnology and pharmaceutical industries, similar to companies like Pfizer, BioNTech, and AstraZeneca.
• The disposition of shares to cover tax withholding obligations upon RSU vesting is also a common and expected practice for executives receiving equity compensation, aligning with practices observed at peer companies.
• The execution of these transactions under a Rule 10b5-1 plan is a widely adopted corporate governance best practice, demonstrating an intent to avoid accusations of trading on material non-public information, consistent with practices at major corporations.

Corporate Governance

Stakeholder Impact

• Shareholders: The transactions are routine and part of executive compensation, aligning management's interests with shareholders through equity ownership. The 10b5-1 plan provides transparency.

Next Steps

• Future quarterly vesting installments for the remaining restricted stock units are expected.

Key Dates

Recommendation

This Form 4 filing details routine, pre-scheduled insider transactions (vesting of restricted stock units and subsequent sales for tax withholding) by a Chief Legal Officer under a 10b5-1 plan. Such transactions are standard for executive compensation and do not typically provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are expected and do not signal a change in management's confidence or a significant shift in company fundamentals. Therefore, a 'hold' recommendation is appropriate as this filing does not present new information to alter an existing investment thesis.

Keywords

Moderna, MRNA, Shannon Thyme Klinger, Chief Legal Officer, Form 4, Insider Trading, Restricted Stock Units, RSU conversion, 10b5-1 plan, Stock transactions, Tax withholding